Induction Chemo-Nivo in Unresectable Stage III NSCLC

Inclusion Criteria: Squamous and non-squamous non-small cell lung cancer that is at baseline, unresectable stage IIIA-IIIC (8th edition AJCC) and not previously treated PD-L1 level needs to be measured with values 0-100% eligible EGFR/ALK/ROS1 Wild Type or unknown genetic alterations in these genes ECOG Performance Status ≤ 1 Adequate organ and marrow function Adequate pulmonary reserve (e.g., FVC, FEV1, TLC, FRC, and DLCO) capable of tolerating the proposed lung resection Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy with undetectable viral load within 6 months For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy, if indicated Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load. Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen Clinical risk assessment of cardiac function using the New York Heart Association Functional Classification class 2B or better Ability to understand and the willingness to sign a written informed consent document Exclusion Criteria: Patients who have participated in a study with an investigational agent or device within 2 weeks of enrollment Any prior radiotherapy to the lung Any prior treatment for NSCLC Any prior therapy with anti-PD-1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or immune checkpoint pathways Any history of a severe hypersensitivity reaction to any monoclonal antibody Any history of allergy to the study drug components primary tumors involving the esophagus pancoast tumors Patients cannot have primary tumors which would remain unresectable History of allergic reactions attributed to compounds of similar chemical or biologic composition to Nivolumab or other agents used in study Any active or history of autoimmune disease (including any history of inflammatory bowel disease), or history of syndrome that required systemic steroids or immunosuppressive medications Ongoing requirement for systemic corticosteroids greater than the equivalent of prednisone 10mg previous malignancies history of interstitial lung disease Patients requiring continuous supplemental oxygen Use of any live vaccines against infectious diseases (e.g., influenza, varicella. etc.) within 4 weeks (28 days) of initiation of study therapy Active systemic infection requiring therapy Patients with uncontrolled intercurrent illness Patients with psychiatric illness/social situations that would limit compliance with study requirements Pregnant or lactating women